Cytek Biosciences achieved record Q4 revenue of $62.1 million, an 8% year-over-year increase. Despite the revenue growth, the company reported a significant net loss of $44.1 million, primarily due to a $38.1 million non-cash valuation allowance against deferred tax assets. Adjusted EBITDA for the quarter was $4.5 million, down from $12.5 million in the prior year due to increased operating expenses.

Cytek Biosciences experienced a slight revenue decrease of 2% in Q2 2025 compared to the previous year, reaching $45.6 million. Despite a challenging macro environment, the company saw steady growth in FSP unit placements and recurring revenue, which grew by 16%. Net loss improved significantly, from $10.4 million in Q2 2024 to $5.6 million in Q2 2025.

Cytek Biosciences reported a decrease in total revenue for the first quarter of 2025 compared to the same period last year, primarily due to a slowdown in product sales in the US and EMEA. Despite this, the company saw strength in the APAC region and double-digit revenue growth in cell sorters and service businesses. Net loss increased compared to the prior year.

Cytek Biosciences reported a Q4 2024 revenue of $57.5 million, a 1.3% decrease compared to Q4 2023. Gross profit increased by 1.8% to $33.7 million, and net income was $9.6 million, including a non-recurring benefit. Adjusted EBITDA was $12.5 million.

Cytek Biosciences reported a 7% increase in revenue compared to the third quarter of 2023, driven by growth in EMEA and APAC regions and service revenue. The company reaffirms its 2024 revenue guidance.

Cytek Biosciences reported a 6% decrease in revenue compared to Q2 2023, totaling $46.6 million, due to U.S. market weakness, though EMEA and APAC regions showed strong growth. The company narrowed its 2024 revenue guidance to $203 million to $210 million and anticipates positive cash flow from operations.

Cytek Biosciences reported a 21% increase in total revenue, reaching $44.9 million in Q1 2024. Organic revenue increased by 11% compared to Q1 2023. The company reaffirms its 2024 revenue guidance, expecting full-year revenue in the range of $203 million to $213 million and anticipates reporting positive net income for the year ending December 31, 2024.

Cytek Biosciences reported a strong fourth quarter with a 21% increase in total revenue, reaching $58.6 million. The company's strategic execution and agility contributed to navigating the challenging macroeconomic environment. Net income for the quarter was $6.3 million, compared to $3.7 million in the same period of the prior year.

Cytek Biosciences reported a 19% increase in total revenue, reaching $48.0 million for the third quarter of 2023. This includes $6.8 million from product lines acquired from Luminex. However, the company experienced a net loss of $6.5 million compared to a net income of $1.6 million in the same period last year.

Cytek Biosciences reported a 24% increase in revenue to $49.7 million for Q2 2023, including $8.2 million from the Luminex acquisition. The company is focused on integrating the Luminex business and expanding its global presence. Net loss was $4.4 million, and adjusted EBITDA was $1.5 million.

Cytek Biosciences reported a 6% increase in total revenue, reaching $37.1 million in Q1 2023. The acquisition of Luminex's flow cytometry and imaging business contributed $3.4 million to the total revenue. Net loss was $6.8 million and adjusted EBITDA was $(2.5) million.

Cytek Biosciences reported a 24% increase in revenue for the fourth quarter of 2022 compared to the same period in 2021, with net income of $3.7 million. The company expanded its installed base and made strategic acquisitions to strengthen its market position. They anticipate continued success in 2023.

Cytek Biosciences reported an 18% increase in total revenue for the third quarter of 2022, reaching $40.5 million. Gross profit margins, net income, and adjusted EBITDA also improved compared to the prior year quarter. The company expanded its installed base to 1,501 instruments, with 142 instrument placements during the quarter.

Cytek Biosciences reported a total revenue of $40.2 million for Q2 2022, a 32% increase compared to Q2 2021. The company expanded its installed base to 1,356 instruments with 130 instrument placements during the quarter and received CE marking for clinical applications in the European market.

Cytek Biosciences reported a strong start to 2022, with first-quarter revenue reaching $35.1 million, a 44% increase compared to the previous year. The company also expanded its installed base to 1,226 instruments and saw growth across its product and service offerings.

Cytek Biosciences reported a strong fourth quarter, with a 27% increase in revenue compared to the previous year. The company also expanded its installed instrument base and enhanced its reagent portfolio through acquisitions and product launches.